Publications by authors named "Elena Netchiporouk"

72 Publications

Clinical and psychosocial factors affecting work productivity among patients with hidradenitis suppurativa: A cluster analytical investigation.

J Am Acad Dermatol 2021 Mar 1. Epub 2021 Mar 1.

Division of Dermatology, McGill University Health Centre, Montreal General Hospital, Rm. L8-201, 1650 Cedar Avenue, Montreal, QC H3G 1A4, Canada. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2021.02.066DOI Listing
March 2021

Non-Melanoma Skin Cancer Distribution in the Russian Federation.

Dermatology 2020 Dec 23:1-9. Epub 2020 Dec 23.

Division of Dermatology, McGill University, Montreal, Québec, Canada,

Background: Non-melanoma skin cancer (NMSC) incidence has been increasing steadily around the world. The aim of the study is to describe geographic trends in incidence and mortality of NMSC in Russia between 2007 and 2017 and compare findings to other European countries.

Methods: We used geospatial analysis to map the incident cases and descriptive statistical analysis to analyze trends. Additionally, we assessed the relationship between ethnicity, geographic latitude/longitude, and NMSC incidence/mortality rates. We retrospectively analyzed the data from the Moscow Oncology Research Institute, Ministry of Health of the Russian Federation, for 2007-2017. Routine methods of descriptive epidemiology were used to study incidence and mortality rates by age groups, years, and jurisdictions (i.e., Federal Districts and Federal Subjects).

Results: In total, 733,723 patients were diagnosed with NMSC in Russia over the period 2007-2017, of whom 63% were women. The overall age-standardized incidence and mortality rates were 29.64/100,000 and 0.70/100,000, respectively. There was a consistent increase in age-standardized incidence rates over the study period, with a decreasing mortality rate. Geographic mapping revealed north-to-south and east-to-west gradients for NMSC.

Conclusions: This study demonstrated longitudinal trends for NMSC incidence in Russia documenting that skin phototype, latitude/longitude, climate zones, and cultural practices remain dominant risk factors defining the epidemiology of NMSC. Moreover, this work identified several regions in the country (i.e., Republic of Adygea, Samara, Krasnodar Krai, etc.), where patient education/sun awareness campaigns will be useful to help reduce the risk of this malignancy.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1159/000512454DOI Listing
December 2020

Inhibition of IL-13: A New Pathway for Atopic Dermatitis.

J Cutan Med Surg 2020 Dec 22:1203475420982553. Epub 2020 Dec 22.

54473 Division of Dermatology, McGill University Health Centre, Montreal, QC, Canada.

Dupilumab, a monoclonal antibody against the common receptor of interleukin (IL)-4 and IL-13, was the first biologic therapy approved in Canada for treatment of moderate-to-severe atopic dermatitis (AD). While it is considered safe and effective, dupilumab is not universally effective and 8%-38% of patients develop conjunctivitis, while some patients develop head and neck dermatitis. Thus, new therapeutic options are warranted. While both IL-4 and IL-13 play important roles in the pathogenesis of AD, it has been recently demonstrated that IL-13 is the primary upregulated cytokine in AD skin biopsy samples. A placebo-controlled phase 2b clinical trial evaluating the efficacy and safety of lebrikizumab, an IL-13 inhibitor, in AD demonstrated that, at 16 weeks, Eczema Area and Severity Index (EASI) 75 and Investigator's Global Assessment (IGA) 0/1 were achieved by 60.6% and 44.6% of patients taking lebrikizumab at its highest dose (vs 24.3% and 15.3% of patients taking placebo, respectively). Moreover, treatment with lebrikizumab was associated with rapid improvement of pruritus and low rates of conjunctivitis (1.4%-3.8%). Another IL-13 monoclonal antibody, tralokinumab, was evaluated for safety and efficacy in moderate-to-severe AD. By week 12, among adults receiving 300 mg tralokinumab, 42.5% achieved EASI-75 and 26.7% achieved IGA 0/1 score (vs 15.5% and 11.8% in the placebo group, respectively). Both lebrikizumab and tralokinumab demonstrated acceptable safety profiles in AD (and non-AD) trials with adverse events often being comparable between treatment and control groups. Thus, IL-13 inhibitors may provide a safe and effective treatment alternative for patients with moderate-to-severe AD.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420982553DOI Listing
December 2020

The Efficacy and Effectiveness of Non-ablative Light-Based Devices in Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis.

Front Med (Lausanne) 2020 3;7:591580. Epub 2020 Nov 3.

Division of Dermatology, McGill University Health Centre, Montreal, QC, Canada.

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder that may be treated with non-ablative light-based devices; however, no systematic reviews on the topic exist to date. We conducted a systematic review and meta-analysis to determine efficacy of non-ablative light-based devices in treating HS. Specifically, a systematic review was conducted using MEDLINE, EMBASE, Web of Science and CINAHL. We analyzed the use of non-ablative light-based devices in the treatment of HS. At least two investigators performed title/abstract review and data extraction. Meta-analysis was conducted using comprehensive meta-analysis software. 5 RCTs and 11 case reports/series were included ( = 211 unique patients). No observational studies were found. For Nd:YAG laser, meta-analysis of 3 RCTs reported improvement in modified HS Lesion Area and Severity Index (HS-LASI) when compared to control subjects. In addition, three case reports/series reported HS-LASI, Physician Global Assessment (PGA) scores and number-of-lesion improvements in treated patients. For intense pulsed light (IPL), two RCTs reported HS-LASI and Dermatology Life Quality Index (DLQI) score improvements. For Alexandrite laser, one case report showed lesion improvement. In conclusion, meta-analysis of Nd:YAG laser in HS patients suggests significant improvement in HS-LASI scores. For IPL, evidence is limited, but suggests improvement in HS-LASI and DLQI scores. For Alexandrite laser, evidence precludes conclusions. Given small sample sizes and inconsistent reporting scales, larger RCTs are required to better determine the efficacy of these modalities in treating HS.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmed.2020.591580DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670045PMC
November 2020

Reply to Reader Comment on "Rituximab Lymphoma-Protocol May Be Superior for Inducing Remission in Pemphigus Vulgaris".

J Cutan Med Surg 2021 Jan-Feb;25(1):113-114. Epub 2020 Nov 10.

54473 Division of Dermatology, McGill University Health Centre, Montreal General Hospital, QC, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420972360DOI Listing
February 2021

Novel variants of and genes in familial hidradenitis suppurativa: A case report.

SAGE Open Med Case Rep 2020 25;8:2050313X20953113. Epub 2020 Sep 25.

Division of Dermatology, McGill University Health Centre, Montreal General Hospital, Montreal, QC, Canada.

We report a two-generation Canadian family of Armenian ancestry with hidradenitis suppurativa where novel mutations in and genes were identified. The father and both children shared a mild-to-moderate hidradenitis suppurativa phenotype together with the features of follicular occlusion (e.g. acne and scalp folliculitis). Based on our findings and previous literature, we recommend considering genetic testing with a periodic fever/autoinflammatory disorder panel in patients with a strong family history of hidradenitis suppurativa and lack of common triggers such as smoking and being overweight.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/2050313X20953113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522817PMC
September 2020

Topical PDE-4 Inhibitors are Emerging for Psoriasis Treatment.

J Cutan Med Surg 2021 Jan-Feb;25(1):109-110. Epub 2020 Sep 30.

SKiN Centre for Dermatology, Peterborough, ON, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420960429DOI Listing
September 2020

Toward Understanding of Environmental Risk Factors in Systemic Sclerosis.

J Cutan Med Surg 2020 Sep 28:1203475420957950. Epub 2020 Sep 28.

54473 Division of Dermatology, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.

Importance: Systemic sclerosis (SSc) is a severe, chronic, and incurable autoimmune fibrotic skin disease with significant extracutaneous involvement. Low concordance rate in twin studies and unequal geographic distribution of SSc argues for importance of environment in disease initiation and progression.

Objective: In this manuscript we provide a summary of all investigated potential external risk factors for SSc.

Data Sources: A literature search in PubMed and EMBASE database was performed for studies published until January 1, 2020 by 2 reviewers (EN and LO) independently.

Findings: Occupational and/or environmental exposures to silica and organic solvents are associated with increased incidence and severity of SSc. Exposure to epoxy resins, asbestos, and particulate air pollution favors increased risk of SSc, but data are based on limited number of observational studies. There is insufficient evidence to conclude an association between SSc development and other occupational (eg, welding fumes) or personal exposures (eg, smoking, vitamin D deficiency). Association of SSc with silicone breast implants has been disproven. Infectious pathogens (eg, and angiotropic viruses) and dysbiosis seem to play a role in SSc development and severity, but their role remains to be clarified.

Conclusions And Relevance: It may be prudent to counsel our patients with SSc (or those at risk of SSc) to avoid occupations with exposure to silica, organic solvents, asbestos and epoxy resins; restraint from smoking, using cocaine or drugs with pro-fibrotic potential. While the association between low vitamin D and SSc remains to be confirmed, we believe that SSc patients should be encouraged to maintain healthy vitamin D levels as benefits outweigh the risks.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420957950DOI Listing
September 2020

Association of Clinical Severity Scores with Psychosocial Impact in Patients with Hidradenitis Suppurativa.

J Am Acad Dermatol 2020 Aug 8. Epub 2020 Aug 8.

Division of Dermatology, McGill University Health Centre, Montreal General Hospital, Rm. L8-201, 1650 Cedar Avenue, Montreal, QC H3G 1A4, Canada. Electronic address:

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.08.022DOI Listing
August 2020

Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].

J Cutan Med Surg 2021 Jan-Feb;25(1):59-76. Epub 2020 Aug 3.

54473507266 Division of Dermatology, McGill University, Montreal, QC, Canada.

Immune checkpoint inhibitors have proven to be efficacious for a broad spectrum of solid organ malignancies. These monoclonal antibodies lead to cytotoxic T-cell activation and subsequent elimination of cancer cells. However, they can also lead to immune intolerance and immune-related adverse event (irAEs) that are new and specific to these therapies. Cutaneous irAEs are the most common, arising in up to 34% of patients on PD-1 inhibitors and 43% to 45% on CTLA-4 inhibitors. The most common skin manifestations include maculopapular eruption, pruritus, and vitiligo-like lesions. A grading system has been proposed, which guides management of cutaneous manifestations based on the percent body surface area (BSA) involved. Cutaneous irAEs may prompt clinicians to reduce drug doses, add systemic steroids to the regiment, and/or discontinue lifesaving immunotherapy. Thus, the goal is for early identification and concurrent management to minimize treatment interruptions. We emphasize here that the severity of the reaction should not be graded based on BSA involvement alone, but rather on the nature of the primary cutaneous pathology. For instance, maculopapular eruptions rarely affect <30% BSA and can often be managed conservatively with skin-directed therapies, while Stevens-Johnson syndrome (SJS) affecting even 5% BSA should be managed aggressively and the immunotherapy should be discontinued at once. There is limited literature available on the management of the cutaneous irAEs and most studies present anecdotal evidence. We review the management strategies and provide recommendations for psoriatic, immunobullous, maculopapular, lichenoid, acantholytic eruptions, vitiligo, alopecias, vasculitides, SJS/toxic epidermal necrolysis, and other related skin toxicities.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420943260DOI Listing
August 2020

Reply to "Comment on: 'Children with chronic urticaria can be effectively controlled with updosing second-generation antihistamines'".

J Am Acad Dermatol 2020 Nov 1;83(5):e365-e366. Epub 2020 Jul 1.

Division of Allergy, Immunology and Dermatology, Montreal Children's Hospital, Montreal, Quebec, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.06.997DOI Listing
November 2020

Preliminary Data Suggests That Biologics in Dermatology Are Not Associated With Adverse COVID-19 Outcomes.

J Cutan Med Surg 2020 Jul/Aug;24(4):420-421. Epub 2020 May 25.

54473507266 Division of Dermatology, McGill University Health Centre, Montreal General Hospital, QC, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420929250DOI Listing
August 2020

Newer and Safer Kappa-Opioid Agonist for Your Patients With Uremic Pruritus.

J Cutan Med Surg 2020 Sep/Oct;24(5):525-526. Epub 2020 May 19.

54473 Division of Dermatology, McGill University Health Centre, Montreal General Hospital, Quebec, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420926989DOI Listing
May 2020

Dysregulations in in Controlling B and T Cell Tolerance Have Important Implications for a Broad Range of Dermatologic Diseases.

J Cutan Med Surg 2020 May/Jun;24(3):312-313

5620 507266 54473 Division of Dermatology, McGill University Health Centre, Montreal, Quebec, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475419890838DOI Listing
May 2020

Ultraviolet Radiation Seeking Behavior, Mediated by Endogenous β-Endorphin, Has Addictive Features.

J Cutan Med Surg 2020 Jul/Aug;24(4):414-415. Epub 2020 May 15.

1236754473 Division of Dermatology, Department of Medicine, McGill University Health Centre, Montreal General Hospital, QC, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420926990DOI Listing
May 2020

Rituximab Lymphoma-Protocol May Be Superior for Inducing Remission in Pemphigus Vulgaris.

J Cutan Med Surg 2020 Sep/Oct;24(5):523-524. Epub 2020 May 13.

54473507266 Division of Dermatology, McGill University Health Centre, Montreal General Hospital, QC, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420926983DOI Listing
May 2020

SB206, a New Topical Nitric Oxide-Releasing Drug on the Horizon for the Treatment of Molluscum Contagiosum and External Anogenital Warts.

J Cutan Med Surg 2020 Jul/Aug;24(4):412-413. Epub 2020 May 13.

562050726654473 Division of Dermatology, Department of Medicine, McGill University Health Centre, Montreal General Hospital, QC, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420926984DOI Listing
May 2020

The Novel Role of Antibiotic Treatment in the Management of Cutaneous T-Cell Lymphoma (CTCL) Patients.

J Cutan Med Surg 2020 Jul/Aug;24(4):410-411. Epub 2020 May 12.

507266 Division of Dermatology, McGill University, Montreal, QC, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420926981DOI Listing
May 2020

Cutaneous Manifestations of Coronavirus Disease 2019 (COVID-19) Infection-What Do We Know So Far?

J Cutan Med Surg 2020 Jul/Aug;24(4):416-417. Epub 2020 May 11.

507266 Division of Dermatology, McGill University Health Center, Montreal, QC, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420928375DOI Listing
August 2020

IncRNAs and circRNAs provide insight into discoid lupus pathogenesis and progression.

Ann Transl Med 2020 Mar;8(6):260

Division of Dermatology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2020.03.56DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186711PMC
March 2020

Artificial Intelligence Applications in Dermatology: Where Do We Stand?

Front Med (Lausanne) 2020 31;7:100. Epub 2020 Mar 31.

Division of Dermatology, McGill University Health Centre, Montreal, QC, Canada.

Artificial intelligence (AI) has become a progressively prevalent Research Topic in medicine and is increasingly being applied to dermatology. There is a need to understand this technology's progress to help guide and shape the future for medical care providers and recipients. We reviewed the literature to evaluate the types of publications on the subject, the specific dermatological topics addressed by AI, and the most challenging barriers to its implementation. A substantial number of original articles and commentaries have been published to date and only few detailed reviews exist. Most AI applications focus on differentiating between benign and malignant skin lesions, however; others exist pertaining to ulcers, inflammatory skin diseases, allergen exposure, dermatopathology, and gene expression profiling. Applications commonly analyze and classify images, however, other tools such as risk assessment calculators are becoming increasingly available. Although many applications are technologically feasible, important implementation barriers have been identified including systematic biases, difficulty of standardization, interpretability, and acceptance by physicians and patients alike. This review provides insight into future research needs and possibilities. There is a strong need for clinical investigation in dermatology providing evidence of success overcoming the identified barriers. With these research goals in mind, an appropriate role for AI in dermatology may be achieved in not so distant future.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmed.2020.00100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136423PMC
March 2020

Recent Advances in Evaluating Impact of Biologic Therapy for Moderate-Severe Psoriasis on Cardiovascular Events and Atherosclerotic Plaque Formation.

J Cutan Med Surg 2020 Mar/Apr;24(2):209-210

54473 507266 Division of Dermatology, MGill University Health Centre, Montreal, QC, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475419890845DOI Listing
February 2021

The Future of Bullous Pemphigoid (BP): New and Promising Drugs May Revolutionize Treatment Course for BP Patients.

J Cutan Med Surg 2020 Mar/Apr;24(2):191-192

54473 507266 Division of Dermatology, McGill University Health Centre, Montreal, QC, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475419888867DOI Listing
February 2021

Dietary Vitamin A Intake Is Shown to Decrease the Risk of Cutaneous Squamous Cell Carcinomas.

J Cutan Med Surg 2020 Mar/Apr;24(2):197-198

54473 507266 Division of Dermatology, McGill University Health Centre, Montreal, QC, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475419890842DOI Listing
February 2021

Spesolimab: A Novel Treatment for Pustular Psoriasis.

J Cutan Med Surg 2020 Mar/Apr;24(2):199-200

54473 507266 Division of Dermatology, McGill University Health Centre, Montreal General Hospital, QC, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475419888862DOI Listing
February 2021

Treatment Modalities for Varicose Veins of Lower Extremities.

J Cutan Med Surg 2020 Mar/Apr;24(2):203-204

54473 507266 Division of Dermatology, McGill University Health Centre, Montreal, QC, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475419891082DOI Listing
February 2021

Ligelizumab Is Superior to Omalizumab for Chronic Spontaneous Urticaria.

J Cutan Med Surg 2020 Mar/Apr;24(2):201-202

54473 Division of Dermatology, McGill University Health Centre, Montreal General Hospital, QC, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475419888873DOI Listing
February 2021

Chronic urticaria in children can be controlled effectively with updosing second-generation antihistamines.

J Am Acad Dermatol 2020 Jun 21;82(6):1535-1537. Epub 2020 Feb 21.

Division of Allergy, Immunology and Dermatology, Montreal Children's Hospital, Montreal, Quebec, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.02.041DOI Listing
June 2020

Time to Change Guidelines for Laboratory Monitoring During Isotretinoin Treatment.

J Cutan Med Surg 2020 Jan/Feb;24(1):92-93

54473 5620 Division of Dermatology, McGill University Health Centre, Montreal, QC, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475419879882DOI Listing
November 2020

Oral Minoxidil: A Possible New Therapy for Androgenetic Alopecia.

J Cutan Med Surg 2020 Jan/Feb;24(1):88-89

54473 Division of Dermatology, McGill University Health Centre, Montréal, QC, Canada.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475419879887DOI Listing
November 2020